Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 4Phase 1 4

Status

Active not recruiting 3Recruiting 1

Sponsor Class

NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1

Interventions

Cyclophosphamide 24Vincristine 19Doxorubicin 17Radiotherapy 14Prednisone 13Methotrexate 13Cytarabine 13Rituximab 11Dexamethasone 11pegaspargase 10Filgrastim 10Etoposide 10Mercaptopurine 9Calcium Dobesilate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8azathiopurine 8auricularum 8Thioguanine 8Leucovorin 8Radiation 7Daunorubicin 7prednylidene 6deltacortene 6Asparaginase 6blinatumomab 5Prednisolone 5Peripheral Blood Stem Cell Transplantation 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Burkitt Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡